Pfizer Inc ((PFE)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Study Overview: Pfizer Inc. is conducting a Phase 3 clinical study titled A 104-Week Study of Ritlecitinib Oral Capsules in Adults With Nonsegmental Vitiligo (Active and Stable) Tranquillo 2. The study aims to evaluate the efficacy, safety, and tolerability of ritlecitinib, a potential oral treatment for nonsegmental vitiligo, a condition causing skin depigmentation. This study is significant as there are currently no approved oral medications for this condition.
Intervention/Treatment: The study tests ritlecitinib in two dosages (50 mg and 100 mg) against a placebo. Ritlecitinib is designed to treat nonsegmental vitiligo by potentially halting or reversing skin depigmentation.
Study Design: This is a randomized, double-blind, placebo-controlled study with a parallel intervention model. Participants are randomly assigned to different treatment groups, and both participants and researchers are unaware of the group assignments to ensure unbiased results. The primary purpose is treatment evaluation.
Study Timeline: The study began on November 8, 2023, with primary completion expected in 2025. The last update was submitted on August 14, 2025. These dates are crucial for tracking the study’s progress and anticipated results.
Market Implications: This study could significantly impact Pfizer’s stock performance and investor sentiment, as successful results may lead to the first approved oral treatment for nonsegmental vitiligo. This could position Pfizer ahead of competitors in the dermatological treatment market.
The study is ongoing, and further details are available on the ClinicalTrials portal.